Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

6 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Combination therapy with AG-490 and interleukin 12 achieves greater antitumor effects than either agent alone.
Burdelya L, Catlett-Falcone R, Levitzki A, Cheng F, Mora LB, Sotomayor E, Coppola D, Sun J, Sebti S, Dalton WS, Jove R, Yu H. Burdelya L, et al. Among authors: catlett falcone r. Mol Cancer Ther. 2002 Sep;1(11):893-9. Mol Cancer Ther. 2002. PMID: 12481410 Free article.
Inhibition of JAK kinase activity enhances Fas-mediated apoptosis but reduces cytotoxic activity of topoisomerase II inhibitors in U266 myeloma cells.
Oshiro MM, Landowski TH, Catlett-Falcone R, Hazlehurst LA, Huang M, Jove R, Dalton WS. Oshiro MM, et al. Among authors: catlett falcone r. Clin Cancer Res. 2001 Dec;7(12):4262-71. Clin Cancer Res. 2001. PMID: 11751528 Free article.
Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression.
Epling-Burnette PK, Liu JH, Catlett-Falcone R, Turkson J, Oshiro M, Kothapalli R, Li Y, Wang JM, Yang-Yen HF, Karras J, Jove R, Loughran TP Jr. Epling-Burnette PK, et al. Among authors: catlett falcone r. J Clin Invest. 2001 Feb;107(3):351-62. doi: 10.1172/JCI9940. J Clin Invest. 2001. PMID: 11160159 Free PMC article.
Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells.
Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernández-Luna JL, Nuñez G, Dalton WS, Jove R. Catlett-Falcone R, et al. Immunity. 1999 Jan;10(1):105-15. doi: 10.1016/s1074-7613(00)80011-4. Immunity. 1999. PMID: 10023775 Free article.